06-09-2018 – TPIV – TapImmune Announces Pricing of $70 Million Private Placement
Financing Led by New Enterprise Associates (NEA) Financing to Close Concurrently with Close of Merger with Marker Therapeutics JACKSONVILLE, Florida, June 8, 2018 – TapImmune Inc. (NASDAQ: TPIV), a clinical-stage immuno-oncology company, today announced that it has entered into security purchase agreements with certain institutional and accredited investors in connection with a private placement of its equity securities. The private placement will be led by New Enterprise Associates (NEA) with participation from Aisling Capital and Perceptive Advisors, among other new and existing investors. The private placement is expected to be completed concurrently with the closing of the proposed merger between TapImmune Inc....
